Neurocrine Biosciences, Inc. (NBIX) Insider Christopher Flint Obrien Sells 6,925 Shares of Stock
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Christopher Flint Obrien sold 6,925 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $61.04, for a total value of $422,702.00. Following the completion of the sale, the insider now owns 55,898 shares in the company, valued at approximately $3,412,013.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Christopher Flint Obrien also recently made the following trade(s):
- On Tuesday, September 5th, Christopher Flint Obrien sold 52,817 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $57.50, for a total value of $3,036,977.50.
- On Thursday, July 27th, Christopher Flint Obrien sold 8,734 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $50.00, for a total value of $436,700.00.
Shares of Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at 61.94 on Wednesday. The stock’s market capitalization is $5.46 billion. Neurocrine Biosciences, Inc. has a one year low of $37.35 and a one year high of $62.90. The company’s 50-day moving average price is $56.42 and its 200 day moving average price is $50.19.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Thursday, August 3rd. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.01). The business had revenue of $6.34 million for the quarter, compared to analyst estimates of $0.61 million. During the same period in the prior year, the firm earned ($0.46) earnings per share. Analysts anticipate that Neurocrine Biosciences, Inc. will post ($2.44) EPS for the current year.
WARNING: “Neurocrine Biosciences, Inc. (NBIX) Insider Christopher Flint Obrien Sells 6,925 Shares of Stock” was published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/neurocrine-biosciences-inc-nbix-insider-christopher-flint-obrien-sells-6925-shares-of-stock/1607198.html.
Several large investors have recently made changes to their positions in NBIX. The Manufacturers Life Insurance Company grew its position in Neurocrine Biosciences by 7.8% in the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after acquiring an additional 193 shares in the last quarter. ARS Investment Partners LLC bought a new stake in Neurocrine Biosciences during the second quarter worth approximately $207,000. Stephens Inc. AR bought a new stake in Neurocrine Biosciences during the second quarter worth approximately $207,000. Ardsley Advisory Partners bought a new stake in Neurocrine Biosciences during the second quarter worth approximately $230,000. Finally, Cubist Systematic Strategies LLC increased its stake in Neurocrine Biosciences by 151.5% during the second quarter. Cubist Systematic Strategies LLC now owns 5,301 shares of the company’s stock worth $244,000 after acquiring an additional 3,193 shares during the last quarter.
A number of brokerages have weighed in on NBIX. Cowen and Company restated an “outperform” rating and issued a $65.00 target price (up from $60.00) on shares of Neurocrine Biosciences in a research note on Wednesday, August 9th. Jefferies Group LLC reiterated a “buy” rating and set a $69.00 price target (up previously from $66.00) on shares of Neurocrine Biosciences in a research report on Tuesday. BidaskClub upgraded Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $70.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday, July 5th. Finally, ValuEngine raised Neurocrine Biosciences from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Two investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Neurocrine Biosciences presently has a consensus rating of “Buy” and an average target price of $68.44.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.